Expert Independent Review
Bioclinica's independent reviewers have experience with the latest advancements in tumor response criteria, imaging modalities and oncology biomarkers, ensuring an innovative solution and world class resources in support of oncology clinical trials with imaging endpoints. Bioclinica's team of board-certified, sub-specialty trained radiologists, nuclear physicians, and medical oncologists analyze all images from baseline to completion with fast turnaround times and can provide a blinded, in-depth oncology response review.
- Sophisticated algorithms for semi-automatic, bi-dimensional, and volumetric tumor measurements
- Custom-designed lesion tracking for longitudinal studies
- Real time derivation for accelerated calculations and reduced error
- Automatic transfer of image analysis data into eCRFs
Network of Key Opinion Leaders (KOL)
As an industry leader in imaging core lab services, Bioclinica has long-standing relationships with a vast network of academic and research key opinion leaders (KOLs) who are available for image review, quality assessment, and imaging charter support. Our KOLs are well recognized for their oncology expertise and provide an additional resource for sponsors planning oncology trials.
Bioclinica has a team of oncology experts and leaders in the field
John Michael O'Neal MD
Dr. O'Neal provides leadership and oversight to Bioclinica's staff radiologists and external radiology consultants. Chief Medical Officer and Head of Oncology, he provides extensive knowledge and oncology experience to the design and implementation of your trial.
Click the names below to learn more about our team of experts.
Oncology Imaging Endpoint Analysis
Imaging endpoints play a central role in oncology trials — determining patient enrollment, prognosis, diagnosis, surveillance, safety, and clinical outcome. Depending on the modality and cancer type, there are many imaging endpoints involving the assessment of tumor responses. These include disease-free survival, objective response rate, time to progression, progression-free survival, and time to treatment failure.
Correct lesion identification and tracking is vital to ensure accurate and precise interpretation during oncology clinical trials. The analysis of oncology imaging endpoints may utilize a number of response criteria, including:
Bioclinica's oncology team has experience with all of these criteria and routinely supports studies using multiple modalities and endpoint analyses.